Gilead Sciences, Inc. to Post Q1 2021 Earnings of $2.03 Per Share, SVB Leerink Forecasts (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) – SVB Leerink raised their Q1 2021 earnings estimates for shares of Gilead Sciences in a research note issued on Tuesday, June 30th. SVB Leerink analyst G. Porges now expects that the biopharmaceutical company will post earnings of $2.03 per share for the quarter, up from their previous forecast of $1.95. SVB Leerink currently has a “Outperform” rating and a $94.00 target price on the stock. SVB Leerink also issued estimates for Gilead Sciences’ Q2 2021 earnings at $2.03 EPS, Q3 2021 earnings at $2.00 EPS, Q4 2021 earnings at $1.88 EPS, FY2021 earnings at $7.94 EPS and FY2022 earnings at $7.89 EPS.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.57 by $0.11. Gilead Sciences had a return on equity of 35.44% and a net margin of 21.84%. The firm had revenue of $5.55 billion during the quarter, compared to the consensus estimate of $5.44 billion. During the same period last year, the company earned $1.67 earnings per share. The company’s revenue for the quarter was up 5.1% on a year-over-year basis.

Several other equities research analysts also recently weighed in on the company. Mizuho reaffirmed a “buy” rating and set a $81.00 price target on shares of Gilead Sciences in a report on Wednesday, May 13th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Tuesday. Royal Bank of Canada reaffirmed a “buy” rating and set a $88.00 price target on shares of Gilead Sciences in a report on Wednesday, June 3rd. Cowen reissued a “buy” rating and issued a $80.00 target price on shares of Gilead Sciences in a report on Monday, April 13th. Finally, Wolfe Research started coverage on Gilead Sciences in a report on Tuesday, March 31st. They issued a “market perform” rating and a $65.00 target price for the company. Five analysts have rated the stock with a sell rating, fifteen have issued a hold rating and ten have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $79.65.

Shares of NASDAQ GILD opened at $76.94 on Wednesday. The company has a debt-to-equity ratio of 1.00, a current ratio of 3.04 and a quick ratio of 2.92. The stock has a fifty day moving average price of $75.41 and a 200 day moving average price of $72.02. Gilead Sciences has a 1-year low of $60.89 and a 1-year high of $85.97. The company has a market cap of $96.51 billion, a PE ratio of 19.78, a P/E/G ratio of 3.37 and a beta of 0.68.

Institutional investors have recently bought and sold shares of the stock. Mid Atlantic Financial Management Inc. ADV increased its holdings in Gilead Sciences by 13.0% during the 4th quarter. Mid Atlantic Financial Management Inc. ADV now owns 15,764 shares of the biopharmaceutical company’s stock valued at $1,024,000 after purchasing an additional 1,813 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its holdings in Gilead Sciences by 0.4% during the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 81,471 shares of the biopharmaceutical company’s stock worth $5,294,000 after acquiring an additional 317 shares in the last quarter. Key Financial Inc bought a new position in Gilead Sciences during the fourth quarter worth about $262,000. Capital One National Association bought a new position in Gilead Sciences during the fourth quarter worth about $543,000. Finally, Wellington Shields & Co. LLC bought a new stake in shares of Gilead Sciences in the fourth quarter valued at about $809,000. Hedge funds and other institutional investors own 80.15% of the company’s stock.

In related news, Director John Francis Cogan sold 2,413 shares of Gilead Sciences stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $79.52, for a total transaction of $191,881.76. Following the completion of the sale, the director now owns 57,273 shares in the company, valued at approximately $4,554,348.96. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Brett A. Pletcher sold 13,210 shares of Gilead Sciences stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $79.23, for a total value of $1,046,628.30. Following the sale, the executive vice president now owns 27,204 shares of the company’s stock, valued at approximately $2,155,372.92. The disclosure for this sale can be found here. In the last 90 days, insiders sold 37,731 shares of company stock valued at $3,008,736. Company insiders own 0.13% of the company’s stock.

The company also recently declared a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Friday, June 12th were given a $0.68 dividend. This represents a $2.72 dividend on an annualized basis and a dividend yield of 3.54%. The ex-dividend date was Thursday, June 11th. Gilead Sciences’s dividend payout ratio is currently 44.30%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Article: How to interpret Moving Average Convergence Divergence (MACD)

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply